If you need help accessing our website, call 855-698-9991
Skip to main content
Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.

Michael H. Pillinger, MD

Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.
  • Specialty: Rheumatology
  • Treats: Adults
  • Language: English

Education and Training
  • Fellowship, NYU School of Medicine, Rheumatology, 1993
  • Residency, Jacobi Medical Center, 1990
  • MD from New York University, 1987

Is this your profile?

Edit profile

Please call the office for information about accepted insurance plans.

Michael H. Pillinger, MD does not accept insurance.


signal transduction and the regulation of cells involved in inflammation and rheumatoid arthritis

Research Summary

In rheumatoid arthritis (RA) the tissues of the involved joints assume inflammatory, autoimmune and pseudoneoplastic features. The cells contributing to these phenotypes include neutrophils, which accumulate in the RA joint space, and synovial fibroblasts (SFs), which proliferate in great numbers in the RA synovium (pannus) and secrete matrix metalloproteinases (MMPs) that participate in the destruction of cartilage.
The mitogen-activated protein kinases (MAPKs) include the Erks, Jnks and p38. Our laboratory is interested in the role of MAPKs on neutrophils and SF regulation. We are especially interested in the role of Erks. We have observed that, in neutrophils, Erk is rapidly activated in response to chemoattractants and regulates neutrophil adhesion, a critical early step in the acute inflammation. In SFs we have shown that Erk regulates proliferation, but also the release of some (MMP-1,3,9) but not other (MMP-13) metalloproteinases. Interestingly, high-dose salicylates (doses achievable in patients but in excess of those needed to inhibit cyclooxygenase) inhibit Erk in both neutrophils and SFs, and concordantly inhibit neutrophil adhesion and SF MMP release. Non-salicylate nonsteroidals also inhibit cyclooxygenase but do not reproduce these effects. Indeed, COX inhibition actually leads to enhancement of MMP release from synovial fibroblasts.
Our present aims are threefold: 1) to understand the mechanisms through which Erk positively regulates neutrophil adhesion; 2) to understand the cross talk between prostaglandin production and Erk activation in SF responses; 3) to understand the mechanisms through which salicylates inhibit Erk, as a clue into how Erk, and other signaling pathways, may be pharmacologically targeted. A better understanding of these phenomena may lead to new approaches, and new agents, for the treatment of RA.}

These focus areas and their associated publications are derived from PubMed and the MeSH term library. *
represents one publication
*Due to PubMed processing times, the most recent publications may not be reflected in the timeline.

  • A Multi-Center Phase 2/3 Randomized Double-Blind Placebo-Controlled Parallel- Group Safety and Efficacy Study of Dapansutrile Tablets in Subjects with an Acute Gout Flare

    Learn More
  • Endothelial Activation in Gout: Early Markers for Cardiovascular Risk

    Learn More
  • SAMPLE (Specimen and Matched Phenotype Linked Evaluation)

    Learn More
View All Research Studies (3)

Read All Publications (243)

Related News